Experts discuss the emerging research into the use of checkpoint inhibitors in gastric and GE junction cancers
This activity is intended for oncologists, gastroenterologists, nurses, and other healthcare professionals who manage patients with gastric cancer.
The goal of this activity is to discuss the emerging role of immunotherapy in patients with gastric and gastroesophageal junction cancers.
Approximate Time to Complete: 45 minutes
Credit Available: Mar. 26, 2019 - Mar. 26, 2020
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the emerging clinical trial data on the management of gastric cancer
- Have greater competence related to selecting the most appropriate treatment regimen in patients with gastric cancer through the continuum of care
- Have greater competence related to managing treatment-related adverse events in patients with gastric cancer